Vitamin K dosing to reverse warfarin based on inr, route of administration, and home warfarin dose in the acute/critical care setting;Dosificación de Vitamina K para Revertir Warfarina en el Escenario de Cuidado Agudo/Cŕtico Basado en INR, Ruta de Administración y Dosis de Warfarina en el Hogar

Annals of Pharmacotherapy

Volumn 46, Issue 12, 2012, Pages 1617-1626

  Tsu, Laura V ^a   Dienes, J Erin ^b   Dager, William E ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Fresh frozen plasma; Phytonadione; Reversal; Vitamin K; Warfarin

Indexed keywords

FRESH FROZEN PLASMA; VITAMIN K GROUP; WARFARIN;

AGED; ANTICOAGULANT THERAPY; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT DURATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; COHORT STUDIES; CRITICAL CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOME CARE SERVICES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMA; RETROSPECTIVE STUDIES; TIME FACTORS; VITAMIN K; WARFARIN;

EID: 84872246051     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R497     Document Type: Review

References (19)

1. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133: 257S-98S. doi: 10.1378/chest.08-0674
2. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006;4:1853-63. doi: 10.1111/j.1538-7836.2006.01986.x
3. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010;29:171-81. doi: 10.1007/s11239-009-0412-5
4. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006;47:804-8. doi: 10.1016/j.jacc.2005.09.058
5. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008;179:235-44. doi: 10.1503/cmaj.080171
6. Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand 2011;55:507-16. doi: 10.1111/j.1399-6576.2011.02414.x
7. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th edition). Chest 2012;141:e152S-84S. doi: 10.1378/chest.11-2295
8. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. doi: 10.1111/j.1538-7836.2005.01204.x
9. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469-73. doi: 10.1001/archinte.163.20.2469
10. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115:145-9. doi: 10.1046/j.1365-2141.2001.03070.x
11. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006;166:391-7. doi: 10.1001/archinte.166.4.391
12. Lubetsky A, Shasha Y, Olchovsky D, Loebstein R, Halkin H, Ezra D. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thromb Haemost 2003;90:71-6.
13. Shetty HG, Backhouse G, Bentley DP, Routledge PA. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992;67:13-5.
14. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-war-farinization. Br J Haematol 2000;109:537-9. doi: 10.1046/j.1365-2141.2000.02001.x
15. Brophy MT, Fiore LD, Deykin D. Low-dose vitamin K therapy in excessively anticoagulated patients: a dose-finding study. J Thromb Thrombolysis 1997;4:289-92.
16. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-3. doi: 10.1016/S0140-6736(00)03125-1
17. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol 2005;46:732-3. doi: 10.1016/j.jacc.2005.05.022
18. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20:1159-66. doi: 10.1592/phco.20.15.1159.34585
19. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002;89:400-6. doi: 10.1016/S1081-1206(10)62042-X